Patient | Gender | Age | Reason to enrol | SUA level (mg/dL) | Previous uric acid-lowering therapy | Number of pegloticase infusions | Reason to discontinue therapy | Initial volume (cm3) | Time between DECTs (days) | Volume reduction (%) |
---|---|---|---|---|---|---|---|---|---|---|
Responders | ||||||||||
1 | F | 55 | Frequent flares | 11.2 | Allopurinol | 12 | Clinical remission | 0.33 | 195 | 96.96 |
2 | M | 43 | Tophaceous gout | 7.7 | Allopurinol | 14 | Clinical remission | 40.79 | 220 | 99.58 |
3 | M | 67 | Frequent flares and tophaceous gout | 5.3 | Allopurinol | 5 | Clinical remission | 8.3 | 298 | 97.10 |
4 | F | 75 | Frequent flares | 10.2 | Allopurinol | 5 | Clinical remission | 0.03 | 151 | 100 |
5 | M | 59 | Frequent flares and tophaceous gout | 4.7 | Benzbromarone | 4 | Clinical remission | 1.06 | 125 | 80.18 |
Partial responders | ||||||||||
1 | M | 55 | Tophaceous gout | 11.4 | Febuxostat | 4 | Allergic reaction, persistent hyperuricaemia | 7.56 | 123 | 29.49 |
2 | M | 43 | Tophaceous gout | 6.9 | Febuxostat | 5 | Allergic reaction, persistent hyperuricaemia | 0.77 | 312 | 81.81 |
3 | F | 67 | Tophaceous gout | 6.3 | Febuxostat | 2 | Allergic reaction, persistent hyperuricaemia | 23.35 | 112 | 73.10 |
4 | M | 55 | Tophaceous gout | 8.5 | Allopurinol | 2 | Allergic reaction, persistent hyperuricaemia | 9.13 | 116 | 29.13 |
5 | M | 63 | Frequent flares and tophaceous gout | 8.6 | Allopurinol | 5 | Allergic reaction, persistent hyperuricaemia | 0.19 | 115 | 26.31 |
DECT, dual-energy CT; SUA, serum uric acid.